The latest biotech news

PBC clinical trials: Gannex doses first patient

News and Trends 16 Aug 2022

Gannex’ first patient dosed in study for treatment of primary biliary cholangitis

A study looking at a treatment for primary biliary cholangitis (PBC) has this month (August) enrolled 12 patients and is expected to be completed by the start of this year’s fourth quarter. Gannex Pharma Co., Ltd., owned by Ascletis Pharma Inc., announced yesterday (August 15) that it had finished its first dosing in the […]

August 16, 2022 - 3 minutesmins - By Liza Laws

News and Trends 16 Aug 2022

Pneumagen embarks on phase 2 proof of concept influenza study

Biotech company Pneumagen says the first person has been dosed in its phase 2 controlled human infection challenge study. Its product, Neumifil, is an intranasal, broad-spectrum antiviral treatment to prevent or, if infected, reduce and manage, viral respiratory tract infections. The phase 2 trial is a single center, randomized, double-blinded, placebo-controlled study evaluating two dose […]

August 16, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 16 Aug 2022

Inhibrx chondrosarcoma treatment gets EC orphan medicinal product designation

Following a positive opinion from the European Medicines Agency (EMA), the European Commission (EC) has granted orphan medicinal product designation to Inhibrx, Inc. for INBRX-109 for the treatment of chondrosarcoma. “We are highly optimistic about the potential of INBRX-109 in chondrosarcoma to address a high unmet medical need,” said Inhibrx CEO, Mark Lappe. “The positive […]

August 16, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 16 Aug 2022

Genentech lymphoma treatment gets FDA approval

Genentech, a part of the Roche Group, says the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Polivy. Polivy (polatuzumab vedotin-piiq), in combination with Rituxan (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of people with previously untreated diffuse large B-cell lymphoma (DLBCL). The FDA […]

August 16, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 16 Aug 2022

Remedium raises more funds for osteoarthritis gene therapy candidate

Remedium Bio, Inc., a biotech company developing novel gene therapies, has closed more than $2.3 million in its expanded seed round financing. Funding from the raise is being used to study Remedium’s lead product, a single-injection gene therapy potentially capable of reversing cartilage loss. The study is being undertaken in a collaboration with Tufts University […]

August 16, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 15 Aug 2022

Opthea secures up to $170M in financing for wet AMD treatment

Opthea Limited, a clinical-stage biopharma company developing novel therapies to treat highly prevalent and progressive retinal diseases, has announced a non-dilutive financing transaction for up to US$170 million from investment funds working with Launch Therapeutics (Launch Tx) to finance and advance the ongoing phase 3 clinical trials and pre-commercialization activities of OPT-302 for wet age-related […]

August 15, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 15 Aug 2022

Approval for Small Pharma major depressive disorder clinical trial

Small Pharma Inc. has received approval from the U.K. Medicines and Healthcare products Regulatory Authority (MHRA) and the Regional Ethics Committee to initiate a drug interaction clinical trial in the U.K. The clinical trial will assess the interaction between serotonin reuptake inhibitors (SSRIs) and SPL026, the company’s lead N, N-dimethyltryptamine (DMT) candidate, in patients with […]

August 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 15 Aug 2022

Scientists develop gel from spider silk proteins for biomedical applications

Researchers at Karolinska Institutet in Sweden and the Swedish University of Agricultural Sciences have discovered spider silk proteins can be fused to biologically active proteins and be converted into a gel at body temperature. One of the goals is to develop an injectable protein solution that forms a gel inside the body, which could be […]

August 15, 2022 - 3 minutesmins - By Jim Cornall

Short Wave Pharma to start anorexia clinical trials

News and Trends 15 Aug 2022

Short Wave Pharma to start clinical trial for anorexia nervosa treatment

Short Wave Pharma Inc., a biopharma company developing patent pending psychedelic compositions and methods of delivery, has signed a clinical trial agreement with the Sheba Fund for Health Services and Research and with Eitan Gur, principal investigator and head of the Sheba Medical Center Department for Eating Disorders, and Yoel Golbert, co–investigator at the center. […]

August 15, 2022 - 3 minutesmins - By Jim Cornall

Roche announces Xofluza approval and new Elecsys IGRA SARS-CoV-2 test

News and Trends 15 Aug 2022

Roche announces influenza drug approval and new COVID test

Roche has announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza in otherwise healthy children aged five to less than 12 years of age who have been symptomatic for no more than 48 hours. This marks […]

August 15, 2022 - 6 minutesmins - By Jim Cornall

News and Trends 15 Aug 2022

Aptinyx fibromyalgia drug misses endpoint

Biopharma company Aptinyx Inc. says its phase 2b clinical study evaluating the effects of NYX-2925 in patients with fibromyalgia did not achieve statistically significant separation from placebo on the study’s primary endpoint. “We are very disappointed that, despite the evidence of activity observed in a prior biomarker study in fibromyalgia patients, in this follow-up phase […]

August 15, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 12 Aug 2022

Tetro Bio-Pharma enters subscription agreement following advice from Alpha Blue Ocean

Tetra Bio-Pharma Inc., a company working in cannabinoid-based drug discovery and development, has announced it has entered into a subscription agreement with investment vehicle Global Corporate Finance Opportunities 16 (GCFO 16). The announcement came yesterday (August 11) after Alpha Blue Ocean (ABO) advised the partnership whereby Canadian-based Tetra agrees to issue investor GCFO 16 senior […]

August 12, 2022 - 2 minutesmins - By Liza Laws

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Gannex’ first patient dosed in study for treatment of primary biliary cholangitis

Pneumagen embarks on phase 2 proof of concept influenza study

Inhibrx chondrosarcoma treatment gets EC orphan medicinal product designation

Genentech lymphoma treatment gets FDA approval

Remedium raises more funds for osteoarthritis gene therapy candidate

Opthea secures up to $170M in financing for wet AMD treatment

Approval for Small Pharma major depressive disorder clinical trial

Scientists develop gel from spider silk proteins for biomedical applications

Short Wave Pharma to start clinical trial for anorexia nervosa treatment

Roche announces influenza drug approval and new COVID test

Aptinyx fibromyalgia drug misses endpoint

Tetro Bio-Pharma enters subscription agreement following advice from Alpha Blue Ocean

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!